Orthofix Medical (OFIX) Stifel 2025 Healthcare Conference summary

Financial performance and recent results

• Achieved Q3 revenue and EBITDA above consensus, with $2.5 million in free cash flow and 6% revenue growth; marked seventh consecutive quarter of EBITDA margin expansion.

• U.S. spine and orthopedics outperformed the market, with strong growth attributed to new strategies and distribution improvements.

• Q3 revenue beat was driven by early international stocking orders, not a change in underlying guidance.

• U.S. businesses are maintaining or accelerating growth into Q4.

U.S. spine business and growth drivers

• U.S. spine procedure growth is above market, supported by competitive product lines and innovation investments.

• Price erosion in U.S. spine is expected to be 1%-2% long-term, but recent pricing has been flat excluding one account.

• Distributor consolidation is ongoing, focusing on scaling and building strong partnerships, expected to remain a growth driver.

• Top 30 distributors are being prioritized for scale and loyalty, leveraging industry relationships.

Capital equipment and enabling technologies

• 7D placement demand increased year-over-year; earnout agreements (Voyager program) reduce upfront capital needs and drive implant utilization.

• Accounts with 7D show 50% higher implant utilization than initial commitments, indicating strong product quality.

• Earnout programs are well received, offering free software updates and maintenance, enhancing customer experience.